Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus FORADIL CERTIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus FORADIL CERTIHALER.
AEROLATE III vs FORADIL CERTIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
One inhalation (12 mcg) twice daily via oral inhalation.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Category C
Category C
Bronchodilator
Bronchodilator